Anthony Jarkowski

Company: Bristol Myers Squibb

Job title: Executive Director, Early Development & Program Lead

Seminars:

Exploring the Adjuvant vs. Neoadjuvant Debate 12:30 pm

Understanding Nivolumab with chemotherapy as neoadjuvant treatment Discussing the data for adjuvant vs. neoadjuvant based on disease stage, actionable mutation status and PD-L1 status Delving into the thoughts and future directions of this dynamic conversationRead more

day: Day Two